True Collaboration, Based in Domain Expertise
Ephicacy does far more than provide resources. We work collaboratively, acting as a true partner across the full spectrum of skills needed for the development and marketing approval of your product. We adapt to share biometrics responsibilities based on your capacity and requirements, whether your internal team will complete some of the work, Ephicacy will fully own deliverables, or somewhere in between. This enables you to take advantage of core competencies internally while also accessing our deep expertise and extensive capacity, resulting in greater efficiency and quality.
For any delivery model, you can count on:
- Aligned, 24/7 global support
- Cost-effective delivery
- Agile ramp-up
- Expert analysts, consultants, and programmers
- Seamless integration with your internal teams
-
Functional Service Provider Model (FSP) Ongoing Support
Ongoing Support
- Global, cost-effective resourcing
- Deep domain expertise
- Solutions tailored to client-specific environments
Explore Our FSP Model
-
Project-Based Service Model
Project-Specific Support
- End-to-end Ephicacy ownership and accountability
- Customized solutions for your program data needs
Discover Project-Based Solutions
-
Clinical Development Consulting
Expert Guidance
- Early insights into design efficiency and compliant studies
- Guidance on regulatory authority interactions
- Extensive time and cost savings via expert modeling
- Standardized data flows and CDISC compliance
Learn More About Consulting
Hybrid Models
If you have multiple projects with varying support needs, or if your requirements fall somewhere in between these options, Ephicacy also offers hybrid models. By blending FSP and project-based models, we can provide support exactly where and how you need it. Reach out to discuss flexible biometrics services that adapt to you.
Hear From Our Clients
“You have displayed admirable characteristics which lead to a more trusting and effective partnership. As we work together effectively, we are showing great benefit to our studies and most importantly to our patients. I hope to continue a close and successful working relationship with you.”
Therapeutic Area Asset Lead, Large Biopharma